Bruce,
I was aware of what you're saying. I however believe that when the company made the decision to put the Phase 1 Safety Trial into the clinical trials database, they should have committed to keeping it up to date as a way of keeping stockholders informed of progress.
I believe if they'd have done this, it's possible the trial would have been nas a Phase 1/2 if in fact they have now added patients who did have a variety of skin diseases.
In the information you were given, all participants for the trial were established, and that should have resulted in the trial being completed in July, as scheduled. The addition of patients with skin diseases goes undocumented, except by investors who've spoken with the company. Had the clinical trials database been updated, we'd not be speculating about this, and when the trial might end, it would be documented.
I know companies like to believe they're maintaining a competitive advantage by not openly discussing what they're doing. I would suspect that any true competitors already know what's happening in the trial as they have sources at the Sheba Hospital. Furthermore, under confidentiality agreements the company is probably speaking with many other companies who potentially could handle their products in various Countries and State's around the world, they too know what's going on. In short, I believe it's largely the shareholders who lack the knowledge of what's happening, and that lack of knowledge is why the share price is so weak.
Frankly the company's actions have permitted those of us who believe in the company to purchase more shares at lower prices than we anticipated, so long term this could be very positive. On the other hand, I don't believe that the company shouldn't pursue maintaining growth in the share price, so I cannot completely agree with their strategy.
I would hope that by the end of the year the safety trial will be completed, and that investors will be thrilled with results. If that is the case, we might very well see new highs if they also present a plan that anticipates product sales in a reasonable amount of time. To me it would not be reasonable if they said that no product would be sold until full blown U.S. FDA drug trials were completed, and our drugs had U.S. approvals which generally are accepted in much of the world. I say this because such trials could take the better part of a decade, depending on what the U.S. demanded in proof that the products are worthy of approval.
I don't know that Mediq will be first to achieve sales. I have no idea how many companies the company may be speaking with regarding rights to other parts of the world. In time I believe we'll see other announcements, but perhaps it will be just one. We've all seen the Pfizer rumor, but the truth is, any of the big Pharma's could handle the products worldwide. On the other hand, companies like Mediq exist in most countries, and agreements with such companies may in the long term be more profitable to OWCP than if they did one major partnership or on the other hand were bought out by big Pharma.
Gary
I was aware of what you're saying. I however believe that when the company made the decision to put the Phase 1 Safety Trial into the clinical trials database, they should have committed to keeping it up to date as a way of keeping stockholders informed of progress.
I believe if they'd have done this, it's possible the trial would have been nas a Phase 1/2 if in fact they have now added patients who did have a variety of skin diseases.
In the information you were given, all participants for the trial were established, and that should have resulted in the trial being completed in July, as scheduled. The addition of patients with skin diseases goes undocumented, except by investors who've spoken with the company. Had the clinical trials database been updated, we'd not be speculating about this, and when the trial might end, it would be documented.
I know companies like to believe they're maintaining a competitive advantage by not openly discussing what they're doing. I would suspect that any true competitors already know what's happening in the trial as they have sources at the Sheba Hospital. Furthermore, under confidentiality agreements the company is probably speaking with many other companies who potentially could handle their products in various Countries and State's around the world, they too know what's going on. In short, I believe it's largely the shareholders who lack the knowledge of what's happening, and that lack of knowledge is why the share price is so weak.
Frankly the company's actions have permitted those of us who believe in the company to purchase more shares at lower prices than we anticipated, so long term this could be very positive. On the other hand, I don't believe that the company shouldn't pursue maintaining growth in the share price, so I cannot completely agree with their strategy.
I would hope that by the end of the year the safety trial will be completed, and that investors will be thrilled with results. If that is the case, we might very well see new highs if they also present a plan that anticipates product sales in a reasonable amount of time. To me it would not be reasonable if they said that no product would be sold until full blown U.S. FDA drug trials were completed, and our drugs had U.S. approvals which generally are accepted in much of the world. I say this because such trials could take the better part of a decade, depending on what the U.S. demanded in proof that the products are worthy of approval.
I don't know that Mediq will be first to achieve sales. I have no idea how many companies the company may be speaking with regarding rights to other parts of the world. In time I believe we'll see other announcements, but perhaps it will be just one. We've all seen the Pfizer rumor, but the truth is, any of the big Pharma's could handle the products worldwide. On the other hand, companies like Mediq exist in most countries, and agreements with such companies may in the long term be more profitable to OWCP than if they did one major partnership or on the other hand were bought out by big Pharma.
Gary
